BRIEF published on 04/15/2025 at 10:05, 8 months 4 days ago IOmx Therapeutics Gains Approval for IOMX-0675 Clinical Trials Immune Response IOmx Therapeutics IOMX-0675 Clinical Trial Approval Solid Tumor Therapy
BRIEF published on 04/15/2025 at 10:05, 8 months 4 days ago IOmx Therapeutics obtient l'approbation pour les essais cliniques sur IOMX-0675 Réponse Immunitaire IOmx Therapeutics IOMX-0675 Approbation Des Essais Cliniques Thérapie Des Tumeurs Solides
PRESS RELEASE published on 04/15/2025 at 10:00, 8 months 4 days ago iOmx Therapeutics Receives Regulatory Approval of Clinical Trial Application for IOMX-0675 iOmx Therapeutics receives regulatory approval for clinical trial application of IOMX-0675, a LILRB1/LILRB2 dual-targeting antibody, to reverse immune suppression in solid tumors Regulatory Approval Clinical Trial Application IOmx Therapeutics IOMX-0675 Solid Tumor
BRIEF published on 12/19/2024 at 14:05, 11 months 30 days ago IOmx Therapeutics Advances IOMX-0675 with Clinical Trial Application Cancer Treatment Clinical Trial Application IOmx Therapeutics IOMX-0675 Immunosuppressive Receptors
BRIEF published on 12/19/2024 at 14:05, 11 months 30 days ago IOmx Therapeutics fait progresser IOMX-0675 avec une application d'essai clinique Traitement Du Cancer Thérapeutique IOmx IOMX-0675 Demande D'essai Clinique Récepteurs Immunosuppresseurs
PRESS RELEASE published on 12/19/2024 at 14:00, 11 months 30 days ago iOmx Therapeutics submits Clinical Trial Application for IOMX-0675 iOmx Therapeutics submits Clinical Trial Application for IOMX-0675, a dual-targeting antibody demonstrating strong anti-tumor potential by reprogramming myeloid cells and restoring cytotoxic T cell function Clinical Trial Application IOmx Therapeutics IOMX-0675 Immunosuppressive Receptors Anti-tumor Potential
BRIEF published on 08/22/2024 at 10:05, 1 year 3 months ago IOmx Therapeutics Initiates Phase Ib with OMX-0407 Cancer Therapy Clinical Trial IOmx Therapeutics OMX-0407 Phase Ib
BRIEF published on 08/22/2024 at 10:05, 1 year 3 months ago IOmx Therapeutics lance la phase Ib avec OMX-0407 Essai Clinique Thérapie Contre Le Cancer OMX-0407 Phase Ib Thérapeutique IOmx
PRESS RELEASE published on 08/22/2024 at 10:00, 1 year 3 months ago iOmx Therapeutics Initiates Phase Ib with OMX-0407 iOmx Therapeutics initiates Phase Ib clinical trial with OMX-0407, showing favorable safety profile and anti-tumor activity in solid tumors. Expansion phase opens in kidney cancer and angiosarcoma Solid Tumors Clinical Trial IOmx Therapeutics OMX-0407 Phase Ib
BRIEF published on 06/27/2024 at 10:05, 1 year 5 months ago IOmx Therapeutics Appoints Florian Schmid as New Chief Financial Officer Chief Financial Officer Biopharmaceutical Leadership IOmx Therapeutics Florian Schmid
Published on 12/19/2025 at 03:15, 7 hours 26 minutes ago Tactical Resources Announces Receipt Of Final Order Approving Arrangement With Plum Acquisition Corp. III
Published on 12/19/2025 at 01:10, 9 hours 31 minutes ago Ostrom Climate Exits Existing UPRIIS ERPA Arrangements
Published on 12/19/2025 at 01:00, 9 hours 41 minutes ago Sun Peak Metals Announces Completion of Acquisition of Saudi Discovery Company SPV Limited
Published on 12/19/2025 at 00:50, 9 hours 51 minutes ago High Resolution Gravity Survey Targets Challenger Repeats
Published on 12/19/2025 at 00:00, 10 hours 41 minutes ago LIR Life Sciences Announces Appointment of Dr. Peter Singer as Scientific Advisor
Published on 12/19/2025 at 10:00, 40 minutes ago Partners Group to sell stake in Australian wind farm
Published on 12/19/2025 at 09:35, 1 hour 5 minutes ago Top sports physio says football bosses failing to properly protect players' health this Christmas as injuries expected to rise
Published on 12/19/2025 at 09:31, 1 hour 9 minutes ago Original-Research: THE NAGA GROUP AG (von NuWays AG): BUY
Published on 12/19/2025 at 08:30, 2 hours 11 minutes ago Share capital decrease by way of treasury shares cancellation
Published on 12/19/2025 at 08:30, 2 hours 11 minutes ago Réduction du capital par voie d’annulation d’actions propres
Published on 12/19/2025 at 07:00, 3 hours 41 minutes ago EURAZEO ANNONCE AVOIR MENÉ AVEC SUCCÈS UNE TRANSACTION ACCÉLÉRANT SA ROTATION D'ACTIFS
Published on 12/19/2025 at 07:00, 3 hours 41 minutes ago EURAZEO ANNOUNCES A SUCCESSFUL TRANSACTION ACCELERATING ITS ASSET ROTATION
Published on 12/18/2025 at 18:30, 16 hours 11 minutes ago Schneider Electric completes transaction to acquire remaining 35% stake in existing Indian JV
